The company’s major shareholders include the reputable institutional investors Hadean Ventures, Industrifonden and Linc, as well as successful life science industry entrepreneurs.
Vipoglanstat (GS-248) is a non-hormonal, potentially disease-modifying drug candidate that inhibits the inflammation-related enzyme mPGES-1. In phase I and II clinical trials, the drug candidate has demonstrated a favorable safety profile and beneficial pharmacological properties. Based on these results and robust data from a preclinical proof-of-concept study in an advanced disease model of endometriosis, vipoglanstat is expected to enter a phase II clinical trial in patients with endometriosis in 2023.Read more
Gesynta Pharma’s pipeline presents a broad range of opportunities based on unique anti-inflammatory and pain-relieving properties. The first compound in this new generation of drug candidates, GS-073, is ready to enter clinical phase I.Read more
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.